Raymond Scott Turner, MD, PhD, is professor of neurology and director of the Memory Disorders program at MedStar Georgetown University Medical Center. Before his recruitment to Georgetown in 2008, he was chief of the neurology service at the VA Ann Arbor Healthcare System and associate professor and associate chair in the Department of Neurology, University of Michigan. Dr. Turner earned his medical degree and a PhD in pharmacology from Emory University, Atlanta, and completed his internship, residency and fellowship at the University of Pennsylvania, Philadelphia. He is board certified in psychiatry and neurology.

Dr. Turner has received numerous prestigious awards, including a fellowship from the Howard Hughes Medical Institute and a Paul Beeson Scholarship. He lectures widely, serves as a reviewer for granting agencies and biomedical journals, and has published more than 70 peer-reviewed papers, editorials and book chapters.

At the MedStar Georgetown Memory Disorders Program, Dr. Turner and his team offer diagnostic services as well as clinical care for older individuals with cognitive disorders. The program also offers a range of research opportunities designed to discover more effective prevention and treatment strategies. To do this, the program partners with healthy older volunteers at risk, as well as individuals with mild cognitive impairment or dementia due to Alzheimer's disease. The program's research is increasingly focused on individuals in the earliest disease stage -- when new treatments may be most effective. Dr. Turner encourages anyone interested in learning more to visit the program website: memory.georgetown.edu

Alzheimer's disease and other progressive dementias of aging are devastating for an individual and his or her family. It is important to seek medical evaluation early if you suspect memory problems are developing. A reversible cause of memory loss may be uncovered, and proven treatments with modest benefits for individuals with Alzheimer's disease are available now. Our team of clinicians have the experience and expertise to provide compassionate and knowledgeable care based on the latest research. We also welcome volunteers and their families to learn about research opportunities and consider participating in a study. This is the only way we will make progress on the war against Alzheimer's disease.

• An individual with human immunodeficiency virus, dementia and central nervous system amyloid deposition. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2016.
• A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015.
• Nilotinib and bosutinib modulate pre-plaque alternations of blood immune markers and neuro-inflammation in Alzheimer's disease models. Neuroscience. 2015.
• Cognitive changes preceding clinical symptom onset of mild cognitive impairment and relationship to ApoE genotype. Current Alzheimer's Research. 2014.
• Cognitive impairment in older patients with breast cancer before systemic therapy: Is there an interaction between cancer and comorbidity? Journal of Clinical Oncology. 2014.

Alzheimer's Talk With Dr. Scott Turner - January 2017